Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 9, 2013, Pages 3477-3482

  McGrath, Danielle M ^a,e   Barbu, E Magda ^a   Driessen, Wouter H P ^a,f   Lasco, Todd M ^b   Tarrand, Jeffrey J ^a   Okhuysen, Pablo C ^c   Kontoyiannis, Dimitrios P ^a   Sidman, Richard L ^d   Pasqualini, Renata ^a   Arap, Wadih ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^f ITHERA MEDICAL GMBH   (Germany)

Author keywords

Antibiotic resistance; Antimicrobial synergism; Bacterial infection; Gram negative bacteria

Indexed keywords

ANTIINFECTIVE AGENT; DEXTRO KLAKLAK; PEPTIDOMIMETIC AGENT; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BIOFILM; CONTROLLED STUDY; ENANTIOMER; LIPID BILAYER; MEMBRANE DAMAGE; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTI-INFECTIVE AGENTS; BACTERIA; BIOFILMS; CELL MEMBRANE; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; KINETICS; LIPID BILAYERS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDOMIMETICS; PHOSPHOLIPIDS; STEREOISOMERISM; TIME FACTORS;

EID: 84874483568     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1221924110     Document Type: Article

References (49)

1. Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group (2005) Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 365(9459): 579-587.
2. Arias CA, Murray BE (2009) Antibiotic-resistant bugs in the 21st century - a clinical super-challenge. N Engl J Med 360(5): 439-443.
3. Klevens RM, et al. (2007) Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 122(2): 160-166.
4. Silva ON, et al. (2011) Exploring the pharmacological potential of promiscuous host-defense peptides: From natural screenings to biotechnological applications. Front Microbiol 2: 232.
5. Lu TK, Collins JJ (2009) Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci USA 106(12): 4629-4634.
6. Boucher HW, et al. (2009) Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1): 1-12.
7. Poole K (2003) Overcoming multidrug resistance in gram-negative bacteria. Curr Opin Investig Drugs 4(2): 128-139.
8. Marr AK, Gooderham WJ, Hancock RE (2006) Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. Curr Opin Pharmacol 6(5): 468-472.
9. Hancock RE, Lehrer R (1998) Cationic peptides: A new source of antibiotics. Trends Biotechnol 16(2): 82-88.
10. Brogden KA (2005) Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3(3): 238-250.
11. Shai Y (1999) Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane- lytic peptides. Biochim Biophys Acta 1462(1-2): 55-70.
12. Huang Y, Huang J, Chen Y (2010) Alpha-helical cationic antimicrobial peptides: Relationships of structure and function. Protein Cell 1(2): 143-152.
13. Pompilio A, et al. (2012) Potential novel therapeutic strategies in cystic fibrosis: Antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol 12: 145.
14. Ladokhin AS, White SH (2001) 'Detergent-like' permeabilization of anionic lipid vesicles by melittin. Biochim Biophys Acta 1514(2): 253-260.
15. Peters BM, Shirtliff ME, Jabra-Rizk MA (2010) Antimicrobial peptides: Primeval molecules or future drugs? PLoS Pathog 6(10):e1001067.
16. Maloy WL, Kari UP (1995) Structure-activity studies on magainins and other host defense peptides. Biopolymers 37(2): 105-122.
17. Bessalle R, Kapitkovsky A, Gorea A, Shalit I, Fridkin M (1990) All-D-magainin: Chirality, antimicrobial activity and proteolytic resistance. FEBS Lett 274(1-2): 151-155.
18. Porter EA, Wang X, Lee HS, Weisblum B, Gellman SH (2000) Non-haemolytic betaamino- acid oligomers. Nature 404(6778): 565.
19. Dathe M, et al. (1997) Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. FEBS Lett 403(2): 208-212.
20. Rothemund S, et al. (1995) Recognition of alpha-helical peptide structures using highperformance liquid chromatographic retention data for D-amino acid analogues: Influence of peptide amphipathicity and of stationary phase hydrophobicity. J Chromatogr A 689(2): 219-226.
21. Javadpour MM, et al. (1996) De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 39(16): 3107-3113.
22. Ellerby HM, et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5(9): 1032-1038.
23. Arap W, et al. (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8(2): 121-127.
24. Lahdenranta J, Sidman RL, Pasqualini R, ArapW(2007) Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease. FASEB J 21(12): 3272-3278.
25. Arap W, et al. (2002) Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 99(3): 1527-1531.
26. Zurita AJ, et al. (2004) Combinatorial screenings in patients: The interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 64(2): 435-439.
27. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W (2004) Reversal of obesity by targeted ablation of adipose tissue. Nat Med 10(6): 625-632.
28. Barnhart KF, et al. (2011) A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med 3(108): 108ra112.
29. Clinical and Laboratory Standards Institute (2013) Performance standards for antimicrobial susceptibility testing. Document M100-S23. Available at http://www.clsi.org/. Accessed January 10, 2013.
30. Müller M, dela Peña A, Derendorf H (2004) Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Distribution in tissue. Antimicrob Agents Chemother 48(5): 1441-1453.
31. Lewis K (2007) Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5(1): 48-56.
32. Berney M, Hammes F, Bosshard F, Weilenmann HU, Egli T (2007) Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLight Kit in combination with flow cytometry. Appl Environ Microbiol 73(10): 3283-3290.
33. Hancock RE, Wong PG (1984) Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 26(1): 48-52.
34. Papo N, Oren Z, Pag U, Sahl HG, Shai Y (2002) The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers. J Biol Chem 277(37): 33913-33921.
35. Arias CA, et al. (2011) Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 365(10): 892-900.
36. Itaka K, Harada A, Nakamura K, Kawaguchi H, Kataoka K (2002) Evaluation by fluorescence resonance energy transfer of the stability of nonviral gene delivery vectors under physiological conditions. Biomacromolecules 3(4): 841-845.
37. van Meer G, Voelker DR, Feigenson GW (2008) Membrane lipids: Where they are and how they behave. Nat Rev Mol Cell Biol 9(2): 112-124.
38. Cronan JE (2003) Bacterial membrane lipids: Where do we stand? Annu Rev Microbiol 57: 203-224.
39. MasonAJ,Marquette A, Bechinger B (2007) Zwitterionic phospholipids and sterols modulate antimicrobial peptide-induced membrane destabilization. Biophys J 93(12): 4289-4299.
40. Rahal JJ (2006) Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43(Suppl 2): S95-S99.
41. Verbist L, Verhaegen J, Wouters C, Vandenhoven G; Multicentre Study Group (1996) Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. J Antimicrob Chemother 37(2): 285-293.
42. Costerton JW, et al. (1987) Bacterial biofilms in nature and disease. Annu Rev Microbiol 41: 435-464.
43. Merritt JH, Kadouri DE, O'Toole GA (2005) Growing and analyzing static biofilms. Curr Protoc Microbiol Chapter 1:Unit1B.1.1-1B.1.18.
44. Hurdle JG, O'Neill AJ, Chopra I, Lee RE (2011) Targeting bacterial membrane function: An underexploited mechanism for treating persistent infections. Nat RevMicrobiol 9(1): 62-75.
45. Ge Y, et al. (1999) In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 35(1): 45-53.
46. Walsh C (2000) Molecular mechanisms that confer antibacterial drug resistance. Nature 406(6797): 775-781.
47. Chugani S, et al. (2012) Strain-dependent diversity in the Pseudomonas aeruginosa quorum-sensing regulon. Proc Natl Acad Sci USA 109(41):E2823-E2831.
48. Schultz D, Onuchic JN, Ben-Jacob E (2012) Turning death into creative force during biofilm engineering. Proc Natl Acad Sci USA 109(46): 18633-18634.
49. Horton KL, Kelley SO (2009) Engineered apoptosis-inducing peptides with enhanced mitochondrial localization and potency. J Med Chem 52(10): 3293-3299.